beta

ALKS

Alkermes plc

Alks

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

10-23-2018 07-26-2018 04-26-2018 02-14-2018 10-26-2017 07-27-2017 04-27-2017
Actual EPS -0.08 0.09 -0.2 0.2 -0.09 -0.13 -0.31
Consensus EPS -0.29 -0.11 -0.01 -0.15 -0.26 -0.24
Estimated EPS -0.29 -0.11 -0.01 -0.15 -0.26 -0.24
Number of Estimates 2 2 2 3 1 2
EPS Surprise $0.21 $0.20 $0.21 $0.06 $0.13 -$0.07

Stats

Summary

Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.

Market Cap: 9.2 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.alkermes.com

Shares Outstanding: 154 Million

Float: 152 Million

Dividend: 0.0 (0.0%)

Beta: 1.986142

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 11.6 Million

Ethical Flags

Animal testing

Longest drawdown: 740 trading days

From: 2015-12-28 To: 2018-12-14

Lowest Point:

Alkermes submits U.S. marketing application for diroximel fumarate for relapsing MS

via: SeekingAlpha at 2018-12-17 08:02:46:000

Alkermes plc (NASDAQ: ALKS ) has filed a New Drug Application (NDA) with the FDA seeking approval for VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Alkermes plc, Biogen Inc., Healthcare stocks news, Read more … read more...

Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis

via: PR Newswire at 2018-12-17 07:30:00:000

DUBLIN and CAMBRIDGE, Massachusetts , Dec. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) and Biogen Inc.(Nasdaq: BIIB) today announced that Alkermes has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate&#xA… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

60 Minutes to air piece on opioid drugmakers and distributors Sunday

via: SeekingAlpha at 2018-12-14 13:50:08:000

CBS' 60 Minutes will air a segment this Sunday featuring Ohio governor-elect Mike DeWine (formerly the AG) criticizing certain drug companies and distributors over their role in the opioid crisis. According to reporter Bill Whitaker, Mr. DeWine says the evidence, obtained from the confiden… read more...

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS … read more...

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS … read more...

Alkermes Looks To FDA For Approval Of Schizophrenia Drug

via: SeekingAlpha at 2018-12-06 13:38:53:000

Recently, Alkermes Plc ( ALKS ) announced results from its second phase 3 study treating patients with schizophrenia. These next set of results will allow the company to file a New Drug Application (NDA) for FDA approval by mid 2019. The reduced amount of weight gain for those taking ALKS … read more...

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock… read more...

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock… read more...

Alkermes' ALKS 3831 successful in late-stage schizophrenia study; shares up 6% premarket

via: SeekingAlpha at 2018-11-29 07:31:56:000

Alkermes plc (NASDAQ: ALKS ) announces positive topline results from a Phase 3 clinical trial, ENLIGHTEN-2 , evaluating orally administered ALKS 3831 (olanzapine/samidorphan) in patients with schizophrenia. More news on: Alkermes plc, Eli Lilly and Company, Healthcare stocks news, Stock… read more...

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the tre… read more...

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the tre… read more...

Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia

via: PR Newswire at 2018-11-29 07:01:00:000

DUBLIN , Nov. 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive topline results from ENLIGHTEN-2, a pivotal phase 3 study of ALKS 3831 (olanzapine/samidorphan), an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the tre… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-16 11:32:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

via: Business Wire at 2018-11-15 22:52:00:000

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alkermes plc (Alkermes or the Company) (NASDAQ: ALKS ) for violations of 10(b) and 20(a) of the Securities Ex… read more...

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc - ALKS

via: Business Wire at 2018-11-15 16:13:00:000

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc. (NASDAQ:ALKS) resulting from allegations that Alkermes may have issued materially misleading business information to the investing publ… read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Leerink sees 34% upside in Allergan in premarket analyst action

via: SeekingAlpha at 2018-11-13 08:20:25:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

NEW YORK , Nov. 9, 2018 /PRNewswire/ --Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc("Alkermes" or the "Company") (NASDAQ: ALKS) resulting from allegations t… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

NEW YORK , Nov. 9, 2018 /PRNewswire/ --Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc("Alkermes" or the "Company") (NASDAQ: ALKS) resulting from allegations t… read more...

Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS

via: PR Newswire at 2018-11-09 11:10:00:000

NEW YORK , Nov. 9, 2018 /PRNewswire/ --Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alkermes plc("Alkermes" or the "Company") (NASDAQ: ALKS) resulting from allegations t… read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

FDA Panel Rejection Of Alkermes Depression Drug Is Good News For Allergan

via: SeekingAlpha at 2018-11-06 18:17:58:000

Allergan (AGN) had some good news last week, though not directly related to it, in the form of an FDA panel rejection vote for Alkermes ( ALKS ) depression drug candidate ALKS-5461. In a clear and decisive vote last Thursday afternoon, the Psychopharmacologic Drugs Advisory Committee (PDAC) … read more...

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov. 13, 2018 at 10:20 a.m. MT ( 12:20 p.m. ET / 5:20 p.m. GMT ) from Sco… read more...

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov. 13, 2018 at 10:20 a.m. MT ( 12:20 p.m. ET / 5:20 p.m. GMT ) from Sco… read more...

Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

via: PR Newswire at 2018-11-06 16:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, Nov. 13, 2018 at 10:20 a.m. MT ( 12:20 p.m. ET / 5:20 p.m. GMT ) from Sco… read more...

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes plc ( ALKS +3.1% ) is up on modestly higher volume on the heels of its announcement of early-stage data on ALKS 4230 that will be presented at SITC this week. More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, , Read more … read more...

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes plc ( ALKS +3.1% ) is up on modestly higher volume on the heels of its announcement of early-stage data on ALKS 4230 that will be presented at SITC this week. More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, , Read more … read more...

Alkermes up 3% on accelerated plan for ALKS 4230

via: SeekingAlpha at 2018-11-06 13:43:07:000

Alkermes plc ( ALKS +3.1% ) is up on modestly higher volume on the heels of its announcement of early-stage data on ALKS 4230 that will be presented at SITC this week. More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, , Read more … read more...

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting in Washington, D.C. , Nov. 9-11, 2018 . Initial clinical data from the ongoing monothera… read more...

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting in Washington, D.C. , Nov. 9-11, 2018 . Initial clinical data from the ongoing monothera… read more...

Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting

via: PR Newswire at 2018-11-06 08:01:00:000

DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting in Washington, D.C. , Nov. 9-11, 2018 . Initial clinical data from the ongoing monothera… read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Stocks making the biggest move premarket: AAPL, SBUX, BABA, NWL, KORS & more

via: CNBC at 2018-11-02 07:50:00:000

No summary available. read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Headquartered in Dublin, Ireland, Alkermes (ALKS) is mainly focused on developing and commercializing therapies targeting conditions such as schizophrenia, depression, addiction, and multiple sclerosis, a ll of which the company characterizes as the central nervous system, or CNS, disorders. … read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Headquartered in Dublin, Ireland, Alkermes (ALKS) is mainly focused on developing and commercializing therapies targeting conditions such as schizophrenia, depression, addiction, and multiple sclerosis, a ll of which the company characterizes as the central nervous system, or CNS, disorders. … read more...

Alkermes Is Making All The Right Moves In 2018

via: SeekingAlpha at 2018-11-02 07:41:46:000

Headquartered in Dublin, Ireland, Alkermes (ALKS) is mainly focused on developing and commercializing therapies targeting conditions such as schizophrenia, depression, addiction, and multiple sclerosis, a ll of which the company characterizes as the central nervous system, or CNS, disorders. … read more...

Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder

via: PR Newswire at 2018-11-01 18:47:00:000

DUBLIN , Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, appointed by the U.S. Food and Drug Administration (FDA), met to review the company's … read more...

FDA Ad Com thumbs down on Alkermes' buprenorphine/samidorphan

via: SeekingAlpha at 2018-11-01 16:01:55:000

FDA advisory committees voted 20-3 against approval for Alkermes' (NASDAQ: ALKS ) buprenorphine and samidorphan sublingual tablets for the adjunctive treatment of major depressive disorder. More news on: Alkermes plc, Healthcare stocks news, Stocks on the move, Read more … read more...

Trading in Alkermes Ordinary Shares Halted Today

via: PR Newswire at 2018-11-01 07:00:00:000

DUBLIN , Nov. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Comm… read more...

Alkermes down 6% premarket ahead of Ad Com for buprenorphine/samidorphan for MDD

via: SeekingAlpha at 2018-10-30 08:04:40:000

Alkermes plc (NASDAQ: ALKS ) is down 6% premarket on light volume in response to the release of briefing documents for Thursday's FDA advisory committee meeting to review and discuss its marketing application seeking approval for buprenorphine and samidorphan sublingual tablets… read more...

Alkermes down 6% premarket ahead of Ad Com for buprenorphine/samidorphan for MDD

via: SeekingAlpha at 2018-10-30 08:04:40:000

Alkermes plc (NASDAQ: ALKS ) is down 6% premarket on light volume in response to the release of briefing documents for Thursday's FDA advisory committee meeting to review and discuss its marketing application seeking approval for buprenorphine and samidorphan sublingual tablets… read more...

Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry

via: PR Newswire at 2018-10-29 13:19:00:000

ALKS 5461 DemonstratedConsistent Profile of Antidepressant Activity, Safety and Tolerability in Two Phase 3 Studies New Drug Application for ALKS 5461 Currently Under FDA Review With Target Action Date of Jan. 31, 2019 DUBLIN , … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-10-26 07:42:46:000

Noteworthy events for the week of October 28 - November 3 for healthcare investors. More news on: TherapeuticsMD, Newron Pharmaceuticals SPA, Enanta Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of an aggregate of $1 millionin grants for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and s… read more...

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of an aggregate of $1 millionin grants for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and s… read more...

Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®

via: PR Newswire at 2018-10-26 07:00:00:000

DUBLIN , Oct. 26, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the recipients of an aggregate of $1 millionin grants for the implementation of innovative, high-impact and replicable programs designed to support people affected by mental health and s… read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

Trump signs STOP Act aimed at opioid crisis

via: SeekingAlpha at 2018-10-24 09:24:12:000

President Trump signs the STOP Act today, sweeping bipartisan legislation aimed at addressing the opioid crisis. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

Alkermes (ALKS) CEO Richard Pops on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-23 15:17:04:000

Alkermes Plc (ALKS) Q3 2018 Earnings Conference Call October 23, 2018 8:30 AM ET Executives Sandy Coombs Co-Head of Investor Relations Jim Frates Senior Vice President, Chief Financial Officer and Treasurer Richard Pops Chairman and Chief Executive Offi… read more...

Alkermes plc 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-23 10:16:06:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q3 earnings Read more … read more...

Alkermes Q3 revenues up 14%

via: SeekingAlpha at 2018-10-23 07:50:20:000

Alkermes ( ALKS ) Q3 results: Revenues: $248.7M (+14.4%); Manufacturing and royalty revenues: $116.4M (-5.1%); Product sales: $116M (+23.8%); R&D revenue: $16.3M. More news on: Alkermes plc, Healthcare stocks news, Earnings news and commentary, Read more … read more...

Alkermes beats by $0.14, beats on revenue

via: SeekingAlpha at 2018-10-23 07:01:41:000

Alkermes (NASDAQ: ALKS ): Q3 Non-GAAP EPS of $0.07 beats by $0.14 ; GAAP EPS of -$0.22 beats by $0.24 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports Third Quarter 2018 Financial Results

via: PR Newswire at 2018-10-23 07:00:00:000

Third Quarter Revenues Increased to $248.7 Million , Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales Company Reports GAAP Net Loss per Share of $0.22 and Diluted Non-GAAP Earnings per Share of $0.07 &#… read more...

Notable earnings before Tuesday's open

via: SeekingAlpha at 2018-10-22 17:30:35:000

ABG , ALKS , ARCH , ASTE , ATI , AVY , AXE , BIIB , CAT , CIT , CNC , DGX , EDU , FBC , FITB , FNB , GATX , GLW , GPK , HBAN , HOG , HUBB , JBLU , LMT , LPT , MBFI , MCD , MMM , NEE , PCAR , PHM , PNR , PPBI , RF , SLCA , SNV , TRU , UTX , VZ , WAT , … read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, 2018 . Poster presentations will include clinical and real-world data related… read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, 2018 . Poster presentations will include clinical and real-world data related… read more...

Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress

via: PR Newswire at 2018-10-17 07:00:00:000

DUBLIN , Oct. 17, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of 10 posters at the upcoming 31 st Annual Psych Congress (Psych Congress) in Orlando , Oct. 25-28, 2018 . Poster presentations will include clinical and real-world data related… read more...

Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results

via: PR Newswire at 2018-10-16 16:01:00:000

DUBLIN , Oct. 16, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Tuesday, Oct. 23, 2018 , to discuss the company's third quarter 2018 financial results. Management will also provide an up… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes plc (NASDAQ: ALKS ) has expanded its Phase 1 clinical trial assessing ALKS 4230 in patients with advanced solid tumors to include a combination with Merck's (NYSE: MRK ) KEYTRUDA (pembrolizumab). More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes plc (NASDAQ: ALKS ) has expanded its Phase 1 clinical trial assessing ALKS 4230 in patients with advanced solid tumors to include a combination with Merck's (NYSE: MRK ) KEYTRUDA (pembrolizumab). More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Alkermes adds Merck's Keytruda to early-stage study of ALKS 4230 in solid tumors

via: SeekingAlpha at 2018-09-10 07:46:50:000

Alkermes plc (NASDAQ: ALKS ) has expanded its Phase 1 clinical trial assessing ALKS 4230 in patients with advanced solid tumors to include a combination with Merck's (NYSE: MRK ) KEYTRUDA (pembrolizumab). More news on: Alkermes plc, Merck & Co Inc., Healthcare stocks news, Read m… read more...

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the F… read more...

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the F… read more...

Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

via: PR Newswire at 2018-09-10 07:00:00:000

DUBLIN , Sept. 10, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has expanded its ongoing phase 1 study for ALKS 4230, the company's immuno-oncology drug candidate, to evaluate its safety and anti-tumor activity when administered in combination with the F… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Senate vote approaches on bill to combat opioid crisis

via: SeekingAlpha at 2018-09-07 12:48:02:000

The Senate will vote next week on the Opioid Crisis Response Act, a lineup of over 70 proposals to fight the opioid crisis following the 50 opioid-related bills that passed the House in June. More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news… read more...

Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

via: PR Newswire at 2018-09-05 07:00:00:000

--ALKERMES Inspiration Grants Program Will Award Up to$1 Millionfor the Development or Expansion of Innovative Programs-- --Applications Now Open for Submission ThroughOct. 2, 2018-- DUBLIN , Sept. 5, 2018 /PRNews… read more...

Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders

via: PR Newswire at 2018-09-05 07:00:00:000

--ALKERMES Inspiration Grants Program Will Award Up to$1 Millionfor the Development or Expansion of Innovative Programs-- --Applications Now Open for Submission ThroughOct. 2, 2018-- DUBLIN , Sept. 5, 2018 /PRNews… read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA updates on multifaceted plan to combat opioid crisis

via: SeekingAlpha at 2018-08-29 12:44:25:000

In a statement , FDA Commissioner Scott Gottlieb, M.D. outlines the FDA's many initiatives aimed at addressing the U.S. opioid crisis. Key points: More news on: Endo International plc, Mallinckrodt PLC, INDIVIOR PLC ADR, Healthcare stocks news, Read more … read more...

FDA clamps down on opioid-peddling websites

via: SeekingAlpha at 2018-08-28 10:57:45:000

The FDA has sent Warning Letters to four additional online networks operating a total of 21 websites for illegally promoting opioids to Americans. The action follows the issuance of 13 Warning Letters to more than 70 websites over the summer. More news on: Endo International plc, Mallinc… read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

FDA awards contract to develop guidelines for opioid prescribing

via: SeekingAlpha at 2018-08-22 11:16:23:000

The FDA has awarded a contract to the National Academies of Sciences, Engineering and Medicine to help advance the development of evidence-based guidelines to help physicians prescribe opioid pain meds in a more appropriate way. More news on: Endo International plc, Mallinckrodt PLC, IND… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

Catalyst-Rich Months Ahead For The Alkermes Pipeline

via: SeekingAlpha at 2018-08-17 14:59:45:000

Significant stock swings due to importance of pipeline Numerous investors in Alkermes ( ALKS ) have noted that attention is now shifting from its marketed drugs, Aristada and Vivitrol, towards several controversial pipeline assets. These assets, ALKS5461, ALKS4230, and ALKS3831, all have sig… read more...

White House proposing cuts in opioid production

via: SeekingAlpha at 2018-08-16 15:24:55:000

Aimed at fighting the U.S. opioid crisis, the Trump administration is proposing production cuts in the most-abused compounds, oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine and fentanyl, by 10% next year. More news on: Endo International plc, Mallinckrodt PLC, Johnson &… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET ( 3:30 p.m. BST ) from Boston . The prese… read more...

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET ( 3:30 p.m. BST ) from Boston . The prese… read more...

Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference

via: PR Newswire at 2018-08-01 16:00:00:000

DUBLIN , Aug. 1, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, Aug. 8, 2018 at 10:30 a.m. ET ( 3:30 p.m. BST ) from Boston . The prese… read more...

Alkermes - 2018 Shaping Into Excellent Year

via: SeekingAlpha at 2018-07-30 08:49:44:000

Alkermes ( ALKS ) recently reported Q2, 2018 earnings. With solid revenues and significant near term catalysts, 2018 is turning into an excellent year. This article explores Alkermes' investment merits. Alkermes' Vivitrol generates solid increasing revenues. Alkermes' Vivitrol is an oldie … read more...

Alkermes - 2018 Shaping Into Excellent Year

via: SeekingAlpha at 2018-07-30 08:49:44:000

Alkermes ( ALKS ) recently reported Q2, 2018 earnings. With solid revenues and significant near term catalysts, 2018 is turning into an excellent year. This article explores Alkermes' investment merits. Alkermes' Vivitrol generates solid increasing revenues. Alkermes' Vivitrol is an oldie … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

FDA accepts Merck KGaA's refiled marketing application for MS med cladribine

via: SeekingAlpha at 2018-07-30 06:58:01:000

The FDA accepts for review Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's resubmitted marketing application seeking approval for MAVENCLAD (cladribine) for the treat of patients with relapsing forms of multiple sclerosis. More news on: Merck KGaA ADR, Biogen Inc., Alkermes plc, Healthcare … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes plc 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:54:12:000

The following slide deck was published by Alkermes plc in conjunction with their 2018 Q2 earnings Read more … read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Sandra Coombs - Alkermes Plc James M. Frates - Alkermes Plc James Robinson - Alkermes Plc Richard F. Pops - Alkermes Plc Analysts Cameron Allen Bradshaw - Bank of America Merrill Lynch Chris S… read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Sandra Coombs - Alkermes Plc James M. Frates - Alkermes Plc James Robinson - Alkermes Plc Richard F. Pops - Alkermes Plc Analysts Cameron Allen Bradshaw - Bank of America Merrill Lynch Chris S… read more...

Alkermes Plc (ALKS) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:36:00:000

Alkermes Plc (ALKS) Q2 2018 Earnings Call July 26, 2018 8:30 am ET Executives Sandra Coombs - Alkermes Plc James M. Frates - Alkermes Plc James Robinson - Alkermes Plc Richard F. Pops - Alkermes Plc Analysts Cameron Allen Bradshaw - Bank of America Merrill Lynch Chris S… read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes beats by $0.15, beats on revenue

via: SeekingAlpha at 2018-07-26 07:01:29:000

Alkermes (NASDAQ: ALKS ): Q2 EPS of $0.29 beats by $0.15 . More news on: Alkermes plc, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 -- -- Company Rei… read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 -- -- Company Rei… read more...

Alkermes Plc Reports Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-26 07:00:00:000

-- Second Quarter Revenues Increase to $304.6 Million , Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 -- -- Company Rei… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-07-25 17:30:13:000

AAL , AAN , AB , ABMD , ADNT , AGN , AIMC , ALK , ALKS , ALLE , ALLY , ALXN , APD , ARD , ASPS , AUO , AXE , AXTA , AZN , BANC , BAX , BC , BMS , BMY , BUD , BWA , CELG , CFR , CMCSA , CME , CMS , CNHI , COLB , COP , COR , COWN , CPG , CRI , CRR , CTS… read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's second quarter 2018 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's second quarter 2018 financial results. Management will also provide an … read more...

Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results

via: PR Newswire at 2018-07-19 16:00:00:000

DUBLIN , July 19, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, July 26, 2018 , to discuss the company's second quarter 2018 financial results. Management will also provide an … read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

Your Daily Pharma Scoop: Redhill's New Patent, Nuvectra Slips, Teligent Gains

via: SeekingAlpha at 2018-07-03 15:18:21:000

Stocks in News: RDHL, NVTR Redhill nabs new patents covering RHB-104 RedHill Biopharma ( RDHL ) announce d that two new patents covering Crohn's disease candidate RHB-104 are notified by USPTO and the European Patent Office. The candidate is currently in Phase 3 development. The paten… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

3 Things In Biotech, July 3: Roche Scores Another Big Win In IO

via: SeekingAlpha at 2018-07-03 08:00:00:000

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Roche goes for a knockout with positive triple-negative data Company: Roche ( RHHBF ) ( RHHBY ) Therapy: Atezoli… read more...

FDA Approves ARISTADA INITIO(TM) for the Initiation of ARISTADA® for Schizophrenia

via: PR Newswire at 2018-07-02 07:01:00:000

DUBLIN , July 2, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO (aripiprazole lauroxil) for the initiation of ARISTADA (aripiprazole lauroxil), a long-acting injec… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-06-21 15:28:40:000

Noteworthy events during the week of June 24 - 30 for healthcare investors. More news on: Roche Holding Ltd ADR, Achaogen, Pain Therapeutics, Healthcare stocks news, Read more … read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Biogen plunges after rival drug for spinal muscular atrophy shows promise

via: CNBC at 2018-06-18 12:33:00:000

No summary available. read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference

via: PR Newswire at 2018-06-06 16:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will participate in a fireside chat at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 3:20 p.m. PT ( … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

SAGE Therapeutics (NASDAQ: SAGE ) initiated with Buy rating and $230 (49% upside) price target at Ladenburg Thalmann. More news on: Sage Therapeutics, Alkermes plc, Inogen, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

SAGE Therapeutics (NASDAQ: SAGE ) initiated with Buy rating and $230 (49% upside) price target at Ladenburg Thalmann. More news on: Sage Therapeutics, Alkermes plc, Inogen, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-06 07:57:02:000

SAGE Therapeutics (NASDAQ: SAGE ) initiated with Buy rating and $230 (49% upside) price target at Ladenburg Thalmann. More news on: Sage Therapeutics, Alkermes plc, Inogen, Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes plc (NASDAQ: ALKS ) has received a $50M payment from licensee Biogen (NASDAQ: BIIB ) after the latter's review of preliminary GI tolerability data on BIIB098 (formerly ALKS 8700), an oral fumarate in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (M… read more...

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes plc (NASDAQ: ALKS ) has received a $50M payment from licensee Biogen (NASDAQ: BIIB ) after the latter's review of preliminary GI tolerability data on BIIB098 (formerly ALKS 8700), an oral fumarate in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (M… read more...

Alkermes receives $50M milestone from Biogen on safety data for MS candidate BIIB098

via: SeekingAlpha at 2018-06-06 07:34:20:000

Alkermes plc (NASDAQ: ALKS ) has received a $50M payment from licensee Biogen (NASDAQ: BIIB ) after the latter's review of preliminary GI tolerability data on BIIB098 (formerly ALKS 8700), an oral fumarate in Phase 3 development for the treatment of relapsing forms of multiple sclerosis (M… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (d… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (d… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile New Drug Application Anticipated for Submission in Q4 2018 DUBLIN , June 6, 2018 /PRNewswire… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

DUBLIN , June 6, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced it has received a $50 million payment from Biogen. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098 (d… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile New Drug Application Anticipated for Submission in Q4 2018 DUBLIN , June 6, 2018 /PRNewswire… read more...

Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program

via: PR Newswire at 2018-06-06 07:00:00:000

Novel, Oral Fumarate Therapy Intended to Provide a Differentiated Gastrointestinal Tolerability Profile New Drug Application Anticipated for Submission in Q4 2018 DUBLIN , June 6, 2018 /PRNewswire… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference

via: PR Newswire at 2018-05-29 16:00:00:000

DUBLIN , May 29, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018 at 1:30 p.m. ET ( 6:30 p.m. BST ) from New York . The presentation may be… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinica… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami , May 29 June 1, 2018 . The poster presentations will high… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinica… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

Long-Term Safety and Clinical Evaluation of Abuse Potential of ALKS 5461 to be Highlighted DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinica… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami , May 29 June 1, 2018 . The poster presentations will high… read more...

Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

via: PR Newswire at 2018-05-23 07:00:00:000

DUBLIN , May 23, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that new clinical data will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami , May 29 June 1, 2018 . The poster presentations will high… read more...

FDA OKs first non-opioid treatment for opioid withdrawal

via: SeekingAlpha at 2018-05-16 16:44:42:000

The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...

FDA OKs first non-opioid treatment for opioid withdrawal

via: SeekingAlpha at 2018-05-16 16:44:42:000

The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-16 07:56:53:000

BioMarin Pharmaceutical (NASDAQ: BMRN ) initiated with Buy rating and $101 (14%upside) price target at Canaccord Genuity. More news on: BioMarin Pharmaceutical Inc., ChemoCentryx, Gemphire Therapeutics, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference

via: PR Newswire at 2018-05-14 16:01:00:000

DUBLIN , May 14, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 21, 2018 at 2:00 p.m. ET ( 7:00 p.m. BST ) from New York . The presentation may be acce… read more...

Alkermes (ALKS) Webinar On ALKS 3831 Drug - Slideshow

via: SeekingAlpha at 2018-05-11 13:34:33:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes (ALKS) Webinar On ALKS 3831 Drug - Slideshow

via: SeekingAlpha at 2018-05-11 13:34:33:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-11 07:48:03:000

Dexcom (NASDAQ: DXCM ) initiated with Buy rating and $100 (18% upside) price target at BofA/Merrill Lynch. More news on: DexCom, Inc., Alkermes plc, National Health Investors Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-11 07:48:03:000

Dexcom (NASDAQ: DXCM ) initiated with Buy rating and $100 (18% upside) price target at BofA/Merrill Lynch. More news on: DexCom, Inc., Alkermes plc, National Health Investors Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference

via: PR Newswire at 2018-05-10 16:01:00:000

DUBLIN , May 10, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16, 2018 at 11:20 a.m. PT ( 2:20 p.m. ET / 7:20 p.m. BST ) from … read more...

Lundbeck Gets An Unexpected Boon From The FDA

via: SeekingAlpha at 2018-05-04 14:58:14:000

Things really do seem a little different at the FDA these days. The FDA's commissioner, Scott Gottlieb, has talked openly of wanting the agency to take a different approach to its interactions with the biopharma industry, speeding up processes, removing certain roadblocks, and generally shifti… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-05-04 09:51:27:000

Noteworthy events during the week of May 6 - 12 for healthcare investors. More news on: Lipocine Inc., Neurovive Pharmaceutical AB, Akcea Therapeutics, Healthcare stocks news, Read more … read more...

Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research

via: PR Newswire at 2018-05-04 07:00:00:000

-- ALKERMES Pathways Research Awards(SM) Program Will Provide Up to $400,000 for Projects Focused on Substance Use Disorder -- -- Applications Open for Submission Now Through Aug. 5, 2018 -- DUBLIN , May 4, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announce… read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-02-13 17:30:16:000

ACCO , AER , AGIO , ALKS , BG , CIGI , CIM , CMS , CRTO , CYRN , DNOW , DPS , FLIR , FUN , GEO , GRPN , HLT , ICL , ICPT , IPG , IQV , LAD , LECO , MZOR , OMI , ORBK , PLAB , SABR , SHPG , SODA , STNG , SUM , TAP , TCX , TECK , WIX , WYN For Seeking … read more...

Wall Street Breakfast: Infrastructure Details Coming Today

via: SeekingAlpha at 2018-02-12 07:07:40:000

The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...

Wall Street Breakfast: Infrastructure Details Coming Today

via: SeekingAlpha at 2018-02-12 07:07:40:000

The White House will roll out a long-awaited infrastructure plan today, which already faces hurdles in Congress because it doesn't offer as much new federal funding as Democrats want, or directly address how to pay for the effort. President Trump will propose spending $200B over 10… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

OxyContin maker stops promoting opioids

via: SeekingAlpha at 2018-02-11 07:37:10:000

OxyContin maker Purdue Pharma is stopping to promote the drug and other opioids to doctors amid a series of state and municipal lawsuits that blame the company for contributing to the opioid epidemic. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Indust… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Healthcare Companies Work To Ease Opioid Crisis

via: SeekingAlpha at 2018-02-09 13:50:02:000

By Marshall Gordon The UN Sustainable Development Goals ( SDGs) , a set of milestones established in 2015 to solve some of the world's most significant social and environmental changes, are seeing increasing acknowledgement and adoption by public companies, shareholders and asset manager… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results

via: PR Newswire at 2018-02-07 16:01:00:000

DUBLIN , Feb. 7, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. GMT ) on Wednesday, Feb. 14, 2018 , to discuss the company's fourth quarter and year-end 2017 financial results. Management will also dis… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

via: SeekingAlpha at 2018-02-02 08:00:00:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss the update from Synergy Pharmaceuticals ( SGYP ), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future diluti… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 31, 2018

via: SeekingAlpha at 2018-02-01 04:01:08:000

Market and sector outlook: Intraday positive reversal in S&P 500 index ( SPY ). Using our VIX indicator, we have a market buy signal and expect a new high before a more meaningful pullback. 10-year yield continued to rise today. Nasdaq Biotechnology Index ( IBB ) was down likely due… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 31, 2018

via: SeekingAlpha at 2018-02-01 04:01:08:000

Market and sector outlook: Intraday positive reversal in S&P 500 index ( SPY ). Using our VIX indicator, we have a market buy signal and expect a new high before a more meaningful pullback. 10-year yield continued to rise today. Nasdaq Biotechnology Index ( IBB ) was down likely due… read more...

U.S. Biotech/Pharma Sector Daily Observations Letter: January 31, 2018

via: SeekingAlpha at 2018-02-01 04:01:08:000

Market and sector outlook: Intraday positive reversal in S&P 500 index ( SPY ). Using our VIX indicator, we have a market buy signal and expect a new high before a more meaningful pullback. 10-year yield continued to rise today. Nasdaq Biotechnology Index ( IBB ) was down likely due… read more...

Alkermes files U.S. marketing application for MDD med ALKS 5461

via: SeekingAlpha at 2018-01-31 15:02:13:000

Alkermes plc ( ALKS -0.1% ) completes the filing of its New Drug Application (NDA) to the FDA seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes files U.S. marketing application for MDD med ALKS 5461

via: SeekingAlpha at 2018-01-31 15:02:13:000

Alkermes plc ( ALKS -0.1% ) completes the filing of its New Drug Application (NDA) to the FDA seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes files U.S. marketing application for MDD med ALKS 5461

via: SeekingAlpha at 2018-01-31 15:02:13:000

Alkermes plc ( ALKS -0.1% ) completes the filing of its New Drug Application (NDA) to the FDA seeking approval for ALKS 5461 for the adjunctive treatment of major depressive disorder (MDD). More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:15:00:000

- New Medicine for Treating Major Depressive Disorder Supported by Comprehensive Efficacy and Safety Data Package From More Than 1,500 Patients - DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:15:00:000

- New Medicine for Treating Major Depressive Disorder Supported by Comprehensive Efficacy and Safety Data Package From More Than 1,500 Patients - DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:15:00:000

- New Medicine for Treating Major Depressive Disorder Supported by Comprehensive Efficacy and Safety Data Package From More Than 1,500 Patients - DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:01:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the a… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:01:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the a… read more...

Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder

via: PR Newswire at 2018-01-31 14:01:00:000

DUBLIN , Jan. 31, 2018 /PRNewswire/ -- Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the a… read more...

Alkermes: A Solid CNS Portfolio With An Option For Depression

via: SeekingAlpha at 2018-01-29 14:15:39:000

Alkermes Overview Alkermes ( ALKS ) is a Central Nervous System (NYSE: CNS ) focused biotech that is based in Dublin, Ireland and also has locations in Massachusetts and Ohio. It has been led by Richard Pops as CEO since 1991. Leadership of Alkermes consists of 17 people including 2 MD'… read more...

Alkermes: A Solid CNS Portfolio With An Option For Depression

via: SeekingAlpha at 2018-01-29 14:15:39:000

Alkermes Overview Alkermes ( ALKS ) is a Central Nervous System (NYSE: CNS ) focused biotech that is based in Dublin, Ireland and also has locations in Massachusetts and Ohio. It has been led by Richard Pops as CEO since 1991. Leadership of Alkermes consists of 17 people including 2 MD'… read more...

Alkermes: A Solid CNS Portfolio With An Option For Depression

via: SeekingAlpha at 2018-01-29 14:15:39:000

Alkermes Overview Alkermes ( ALKS ) is a Central Nervous System (NYSE: CNS ) focused biotech that is based in Dublin, Ireland and also has locations in Massachusetts and Ohio. It has been led by Richard Pops as CEO since 1991. Leadership of Alkermes consists of 17 people including 2 MD'… read more...

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

via: SeekingAlpha at 2018-01-25 14:10:20:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This… read more...

Your Daily Pharma Scoop: Synergy's Trulance Gets Approval In IBS-C, Biogen Announces Q4 Results, Summit's Positive Interim Results

via: SeekingAlpha at 2018-01-25 14:10:20:000

Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we will discuss Synergy Pharmaceuticals ( SGYP ), which as expected has been granted an approval for Trulance 3 mg tablet as a once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults. This… read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm

via: Business Wire at 2018-01-17 18:08:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc (Alkermes or the Company) (NASDAQ:ALKS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been f… read more...

Scott+Scott, Attorneys at Law, LLP Reminds Investors of January 22 Deadline in Securities Class Action Against Alkermes plc (ALKS)

via: Business Wire at 2018-01-17 13:12:00:000

Scott+Scott, Attorneys at Law, LLP (Scott+Scott), a national securities and consumer rights litigation firm, reminds investors that a class action lawsuit is pending against Alkermes plc (NASDAQ: ALKS) (Alkermes or the Company) and certain of… read more...

Your Daily Pharma Scoop: Roche Highlights Pipeline, GenSight Gets Nod To Start Trial, Bluebird Presents At JPM

via: SeekingAlpha at 2018-01-11 03:13:18:000

Analysis of top Seeking Alpha coverage: Roche Today we will focus on Roche ( OTCQX:RHHBY ), which is one of our favorite companies in the large cap biopharma space. The Swiss drugmaker had a solid 2017, gaining more than 10%. While this is below the performance of the IBB for 2017 (up 21… read more...

Alkermes (ALKS) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-10 13:39:39:000

The following slide deck was published by Alkermes plc in conjunction with this Read more … read more...

Alkermes sees 2017 top line as high as $900M

via: SeekingAlpha at 2018-01-10 06:59:03:000

In a presentation at JPM18 yesterday, Alkermes (NASDAQ: ALKS ) CEO Richard Pops updated the company's 2017 guidance. More news on: Alkermes plc, Healthcare stocks news, Read more … read more...

ALKERMES INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alkermes plc To Contact The Firm

via: Business Wire at 2018-01-09 18:23:00:000

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc (Alkermes or the Company) (NASDAQ:ALKS) of the January 22, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been f… read more...

What Is Driving Stocks? - Cramer's Mad Money (1/8/18)

via: SeekingAlpha at 2018-01-09 07:44:05:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, January 8. As the market went higher on Monday, Cramer deduced the reasons for the rally. "First, let's understand: this market is largely driven not by stock-pickers, but by index funds. That index… read more...

Cramer Remix: Tesla's stock is up for one simple reason

via: CNBC at 2018-01-08 19:00:00:000

No summary available. read more...

'Best days are still ahead' for top opioid addiction treatment Vivitrol, CEO says

via: CNBC at 2018-01-08 18:42:00:000

No summary available. read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX